Under active development. Data is being added and corrected on an hourly basis.

← Back to Peptides
SS-31 structure

SS-31

Other
Approved Research
85%
Low Risk
1/5

Dosing Protocol

Typical Dose 40 mg
Range 5 - 40 mg
Maintenance 40 mg daily

Pharmacokinetics

Half-Life 2.0 hrs
Onset 30 min
Peak 1.0 hrs
Duration 6.0 hrs
Bioavailability 90%
Primary Route Subcutaneous

Administration

Routes Subcutaneous, Intravenous
Injection Sites Abdomen, Thigh
Needle Gauge 29-31G
Syringe Type Insulin
Timing Morning

Reconstitution

Diluent Sterile Water
Volume 2 mL
Stability 28 days refrigerated
Vial Sizes 40 mg

Special Instructions

FDA approved for Barth syndrome. Selectively targets mitochondria. Daily dosing for mitochondrial support.